Drug Trial Radar · NCT06543303
Evaluation of BTV100 in Subjects With Dry Eye Disease
Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
Dec 31, 2024
Primary completion
Jan 14, 2026
Study completion Jan 14, 2026
Sponsor
- Lead sponsor
- BioTheraVision, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be a randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study to evaluate the efficacy, safety and tolerability of repeat dosing of Cevimeline Ophthalmic Solution compared to the vehicle in subjects with Dry Eye Disease (DED).
Conditions
- Dry Eye
Interventions
BTV100 Low doseDrug
1% Cevimeline Ophthalmic Solution
BTV100 Mid doseDrug
2% Cevimeline Ophthalmic Solution
BTV100 High doseDrug
4% Cevimeline Ophthalmic Solution
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Schirmer testTime frame: Day 85
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Sydney Eye Hospital
Sydney, Australia
Cataract and Eye Surgery Centre, Victoria
Doncaster East, Victoria, Australia
Chang Gung Memorial Hospital-Kaohsiung Branch
Kaohsiung City, Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Chang Gung Memorial Hospital-LinKou Branch
Taoyuan, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.